首页 > 市场调查报告书 > 医疗设备

医学影像诊断 CT/MRI/X光

全球 PET 放射性示踪剂市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

市场调查报告书

商品编码

1332696

全球 PET 放射性示踪剂市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

Global PET Radiotracer Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，全球 PET 放射性示踪剂市场的市场规模将从 2022 年的 31.7 亿美元达到近 64 亿美元，2023-2030 年研究期间复合年增长率为 9.2%。

PET放射性示踪剂，也称为PET放射性药物或PET示踪剂，是一种用于正电子发射断层扫描（PET）成像的放射性化合物。它是一种核成像技术，可提供体内生理和生化过程的详细图像。

市场动态：

全球范围内癌症患病率的不断上升推动了对放射性示踪剂 PET 成像的需求，这有助于癌症诊断和治疗评估。分子成像的进步和新型放射性示踪剂的开发扩展了 PET 成像的能力，使其适用于各种医学领域和生理过程。对早期疾病检测和个性化医疗的重视进一步推动了对 PET 放射性示踪剂的需求。核医学的研究和开发工作导致了新型放射性示踪剂的发现，增强了 PET 成像的可用性和应用。资金、投资和政府支持的增加促进了 PET 放射性示踪剂的商业化和采用。人口老龄化的不断增长增加了对癌症和神经退行性疾病等与年龄相关的疾病的 PET 成像的需求。 PET 放射性示踪剂在药物开发和临床试验、评估药物疗效和靶点参与方面也至关重要。有利的报销政策以及 PET 与其他成像方式的整合进一步支持了 PET 放射性示踪剂市场的增长。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球宠物放射性示踪剂市场的各个细分市场进行了包容性评估。宠物放射性示踪剂行业的增长和趋势为这项研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 PET 放射性示踪剂市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 PET放射性示踪剂市场的主要参与者包括ABX先进生化化合物有限公司（剑桥同位素实验室公司）、Blue Earth Diagnostics、Cardinal Health.、礼来公司、GE Healthcare、IBA Radiopharma Solutions、Jubilant Pharma Limited、Lantheus Holdings Inc。、西门子Healthineers AG、烟台东诚药业集团有限公司。本部分包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

区域展望
介绍
北美销售分析
- 概览、历史和预测数据销售分析
- 北美按细分市场销售分析
- 北美按国家/地区销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史和预测数据销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家/地区销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史和预测数据销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史和预测数据销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家/地区销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史和预测数据销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：宠物放射示踪剂公司的竞争格局

宠物放射性示踪剂市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)

公司简介
公司收入
产品
最近的发展

Blue Earth Diagnostics

公司简介
公司收入
产品
最近的发展

Cardinal Health.

公司简介
公司收入
产品
最近的发展

Eli Lilly and Company

公司简介
公司收入
产品
最近的发展

GE Healthcare

公司简介
公司收入
产品
最近的发展

IBA Radiopharma Solutions

公司简介
公司收入
产品
最近的发展

Jubilant Pharma Limited

公司简介
公司收入
产品
最近的发展

Lantheus Holdings Inc.

公司简介
公司收入
产品
最近的发展

Siemens Healthineers AG

公司简介
公司收入
产品
最近的发展

Yantai Dungcheng Pharmaceutical Group Co. Ltd.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

简介目录图表

Product Code: VMR112111873

The global demand for PET Radiotracer Market is presumed to reach the market size of nearly USD 6.4 BN by 2030 from USD 3.17 BN in 2022 with a CAGR of 9.2% under the study period 2023 - 2030.

A PET radiotracer, also known as a PET radiopharmaceutical or PET tracer, is a radioactive compound used in Positron Emission Tomography (PET) imaging.It is a nuclear imaging technique that provides detailed images of the physiological and biochemical processes in the body.

MARKET DYNAMICS:

The increasing prevalence of cancer worldwide fuels the demand for PET imaging with radiotracers, which assist in cancer diagnosis and treatment evaluation. Advancements in molecular imaging and the development of new radiotracers expand the capabilities of PET imaging, making it applicable to various medical fields and physiological processes. The emphasis on early disease detection and personalized medicine further drives the demand for PET radiotracers. Research and development efforts in nuclear medicine result in the discovery of novel radiotracers, enhancing the availability and application of PET imaging. Increased funding, investments, and government support boost the commercialization and adoption of PET radiotracers. The growing ageing population contributes to the demand for PET imaging in age-related diseases, such as cancer and neurodegenerative disorders. PET radiotracers are also essential in drug development and clinical trials, assessing drug efficacy and target engagement. Favourable reimbursement policies and the integration of PET with other imaging modalities further support the growth of the PET radiotracer market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pet radiotracer. The growth and trends of pet radiotracer industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pet radiotracer market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Radiotracer Type

F-18 (FDG18)
Ga 68 (FAPI)
Others

By Application

Cancer
Heart Disease
Gastrointestinal
Endocrine
Neurological Disorders
Others

By End-User

Hospitals
Diagnostic Centers
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the PET Radiotracer market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PET Radiotracer market include ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.), Blue Earth Diagnostics, Cardinal Health., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc., Siemens Healthineers AG, Yantai Dungcheng Pharmaceutical Group Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PET RADIOTRACER - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Radiotracer Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY RADIOTRACER TYPE

5.1 Overview by Radiotracer Type
5.2 Historical and Forecast Data
5.3 Analysis by Radiotracer Type
5.4 F-18 (FDG18) Historic and Forecast Sales by Regions
5.5 Ga 68 (FAPI) Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Cancer Historic and Forecast Sales by Regions
6.5 Heart Disease Historic and Forecast Sales by Regions
6.6 Gastrointestinal Historic and Forecast Sales by Regions
6.7 Endocrine Historic and Forecast Sales by Regions
6.8 Neurological Disorders Historic and Forecast Sales by Regions
6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY END-USER

7.1 Overview by End-user
7.2 Historical and Forecast Data
7.3 Analysis by End-user
7.4 Hospitals Historic and Forecast Sales by Regions
7.5 Diagnostic Centers Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PET RADIOTRACER COMPANIES

9.1. Pet Radiotracer Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF PET RADIOTRACER INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Blue Earth Diagnostics
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Cardinal Health.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Eli Lilly and Company
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. GE Healthcare
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. IBA Radiopharma Solutions
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Jubilant Pharma Limited
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Lantheus Holdings Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Siemens Healthineers AG
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Yantai Dungcheng Pharmaceutical Group Co. Ltd.
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments